149 related articles for article (PubMed ID: 31485769)
1. EP3 receptor is a prognostic factor in TA-MUC1-negative ovarian cancer.
Czogalla B; Kuhn C; Heublein S; Schmöckel E; Mayr D; Kolben T; Trillsch F; Burges A; Mahner S; Jeschke U; Hester A
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2519-2527. PubMed ID: 31485769
[TBL] [Abstract][Full Text] [Related]
2. The role of EP3-receptor expression in cervical dysplasia.
Hester A; Ritzer M; Kuhn C; Schmoeckel E; Mayr D; Kolben T; Dannecker C; Mahner S; Jeschke U; Kolben TM
J Cancer Res Clin Oncol; 2019 Feb; 145(2):313-319. PubMed ID: 30402741
[TBL] [Abstract][Full Text] [Related]
3. TA-MUC1 as detected by the fully humanized, therapeutic antibody Gatipotzumab predicts poor prognosis in cervical cancer.
Heublein S; Friese K; Kost B; Marmé F; Kuhn C; Mahner S; Dannecker C; Mayr D; Jeschke U; Vattai A
J Cancer Res Clin Oncol; 2018 Oct; 144(10):1899-1907. PubMed ID: 30062487
[TBL] [Abstract][Full Text] [Related]
4. The prostaglandin receptor EP2 determines prognosis in EP3-negative and galectin-3-high cervical cancer cases.
Dietlmeier S; Ye Y; Kuhn C; Vattai A; Vilsmaier T; Schröder L; Kost BP; Gallwas J; Jeschke U; Mahner S; Heidegger HH
Sci Rep; 2020 Jan; 10(1):1154. PubMed ID: 31980713
[TBL] [Abstract][Full Text] [Related]
5. The Prostaglandin EP3 Receptor Is an Independent Negative Prognostic Factor for Cervical Cancer Patients.
Heidegger H; Dietlmeier S; Ye Y; Kuhn C; Vattai A; Aberl C; Jeschke U; Mahner S; Kost B
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28753926
[TBL] [Abstract][Full Text] [Related]
6. Potential Interplay of the Gatipotuzumab Epitope TA-MUC1 and Estrogen Receptors in Ovarian Cancer.
Heublein S; Page S; Mayr D; Schmoeckel E; Trillsch F; Marmé F; Mahner S; Jeschke U; Vattai A
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30642093
[TBL] [Abstract][Full Text] [Related]
7. EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer.
Semmlinger A; von Schoenfeldt V; Wolf V; Meuter A; Kolben TM; Kolben T; Zeder-Goess C; Weis F; Gallwas J; Wuerstlein R; Hermelink K; Schmoeckel E; Harbeck N; Mayr D; Mahner S; Jeschke U; Ditsch N
BMC Cancer; 2018 Apr; 18(1):431. PubMed ID: 29661238
[TBL] [Abstract][Full Text] [Related]
8. Glycodelin A is a prognostic marker to predict poor outcome in advanced stage ovarian cancer patients.
Scholz C; Heublein S; Lenhard M; Friese K; Mayr D; Jeschke U
BMC Res Notes; 2012 Oct; 5():551. PubMed ID: 23036050
[TBL] [Abstract][Full Text] [Related]
9. EP3 Is an Independent Prognostic Marker Only for Unifocal Breast Cancer Cases.
Zati Zehni A; Jeschke U; Hester A; Kolben T; Ditsch N; Jacob SN; Mumm JN; Heidegger HH; Mahner S; Vilsmaier T
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32580276
[TBL] [Abstract][Full Text] [Related]
10. Breast adipose tissue macrophages (BATMs) have a stronger correlation with breast cancer survival than breast tumor stroma macrophages (BTSMs).
Lin L; Kuhn C; Ditsch N; Kolben T; Czogalla B; Beyer S; Trillsch F; Schmoeckel E; Mayr D; Mahner S; Jeschke U; Hester A
Breast Cancer Res; 2021 Apr; 23(1):45. PubMed ID: 33849622
[TBL] [Abstract][Full Text] [Related]
11. Staining of MUC1 in ovarian cancer tissues with PankoMab-GEX detecting the tumour-associated epitope, TA-MUC1, as compared to antibodies HMFG-1 and 115D8.
Dian D; Lenhard M; Mayr D; Heublein S; Karsten U; Goletz S; Kuhn C; Wiest I; Friese K; Weissenbacher T; Jeschke U
Histol Histopathol; 2013 Feb; 28(2):239-44. PubMed ID: 23275306
[TBL] [Abstract][Full Text] [Related]
12. MUC1 is upregulated in advanced prostate cancer and is an independent prognostic factor.
Genitsch V; Zlobec I; Thalmann GN; Fleischmann A
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):242-7. PubMed ID: 27165976
[TBL] [Abstract][Full Text] [Related]
13. Immunoreactivity of the fully humanized therapeutic antibody PankoMab-GEX™ is an independent prognostic marker for breast cancer patients.
Heublein S; Mayr D; Egger M; Karsten U; Goletz S; Angele M; Gallwas J; Jeschke U; Ditsch N
J Exp Clin Cancer Res; 2015 May; 34(1):50. PubMed ID: 25986064
[TBL] [Abstract][Full Text] [Related]
14. Prostaglandin E2 receptor 3 (EP3) signaling promotes migration of cervical cancer via urokinase-type plasminogen activator receptor (uPAR).
Ye Y; Peng L; Vattai A; Deuster E; Kuhn C; Dannecker C; Mahner S; Jeschke U; von Schönfeldt V; Heidegger HH
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2189-2203. PubMed ID: 32488496
[TBL] [Abstract][Full Text] [Related]
15. M2 Macrophages Infiltrating Epithelial Ovarian Cancer Express MDR1: A Feature That May Account for the Poor Prognosis.
Badmann S; Heublein S; Mayr D; Reischer A; Liao Y; Kolben T; Beyer S; Hester A; Zeder-Goess C; Burges A; Mahner S; Jeschke U; Trillsch F; Czogalla B
Cells; 2020 May; 9(5):. PubMed ID: 32429133
[TBL] [Abstract][Full Text] [Related]
16. The role of MUC1 and MUC3 in the biology and prognosis of colorectal cancer.
Duncan TJ; Watson NF; Al-Attar AH; Scholefield JH; Durrant LG
World J Surg Oncol; 2007 Mar; 5():31. PubMed ID: 17349047
[TBL] [Abstract][Full Text] [Related]
17. Mucin-1 and its relation to grade, stage and survival in ovarian carcinoma patients.
Engelstaedter V; Heublein S; Schumacher AL; Lenhard M; Engelstaedter H; Andergassen U; Guenthner-Biller M; Kuhn C; Rack B; Kupka M; Mayr D; Jeschke U
BMC Cancer; 2012 Dec; 12():600. PubMed ID: 23241107
[TBL] [Abstract][Full Text] [Related]
18. Expression of MUC1 and MUC2 mucin gene products in human ovarian carcinomas.
Feng H; Ghazizadeh M; Konishi H; Araki T
Jpn J Clin Oncol; 2002 Dec; 32(12):525-9. PubMed ID: 12578901
[TBL] [Abstract][Full Text] [Related]
19. Chemoresistance is associated with MUC1 and Lewis y antigen expression in ovarian epithelial cancers.
Zhang D; Gao J; Zhu L; Hu Z; Hou R; Liu S; Tan M; Liu J; Lin B
Int J Mol Sci; 2013 May; 14(6):11024-33. PubMed ID: 23708102
[TBL] [Abstract][Full Text] [Related]
20. Lewis(y) antigen promotes the progression of epithelial ovarian cancer by stimulating MUC1 expression.
Hou R; Jiang L; Liu D; Lin B; Hu Z; Gao J; Zhang D; Zhang S; Iwamori M
Int J Mol Med; 2017 Aug; 40(2):293-302. PubMed ID: 28586014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
